Recent advances in molecular genetics have identified several genes associated with inherited susceptibility to cancer and have provided a means to begin identifying individuals and families with an increased risk of cancer. This rapid expansion of knowledge about cancer genetics has implications for all aspects of cancer management, including prevention, screening, and treatment. These guidelines specifically address hereditary breast/ovarian cancer syndrome (HBOC), Li-Fraumeni syndrome, and Cowden syndrome. These guidelines were developed understanding that much of our knowledge of how the rapidly emerging field of molecular genetics can be applied clinically is preliminary and that flexibility is needed when applying these guidelines to individual families.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
The Stanford Cancer Center is an international leader in cancer research and patient care. The mission of the Stanford Clinical Cancer Program is to provide comprehensive care through multidisciplinary collaboration and integrated services; advance cancer therapies through clinical research; and train future leaders in the treatment of patients with cancer. The collaborative approach to cancer research and treatment is a hallmark of this program.
One hundred and sixty faculty members participate in cancer care and clinical research with over 250 active clinical trials. Stanford researchers and physicians have led the way in developing many of the current state-of-the-art radiology, antibody, and biologic therapies that are used to treat cancers. The Cancer Center also encompasses basic population-based research into the causes and consequences of cancer and supports 16 interdisciplinary disease-related programs.
Steven A. Leibel, MD, is the Medical Director of the Stanford Cancer Center and a professor of Radiation Oncology. He joined Stanford in 2004. Irv Weissman, MD (not pictured), is the Director, and Beverly Mitchell, MD (not pictured), is the Deputy Director of the Stanford University Comprehensive Cancer Center.